ANI To Divest Two And Agree To Other Provisions To Close Novitium Deal
Proposed Merger Anticipated To Close This Month Following FTC Settlement
Executive Summary
Before closing its acquisition of fellow US-based manufacturer Novitium Pharma, ANI Pharmaceuticals must agree to several orders, including divestment of rights and/or assets for two generic products.
You may also be interested in...
ANI Pharmaceuticals Completes $210m Novitium Acquisition
ANI Pharmaceuticals has completed its acquisition of niche generics specialist Novitium Pharma, securing access to a pipeline of generics and 505(b)(2) candidates that has expanded further since the deal was announced earlier in the year.
FDA Guides On Rivals To Primatene Mist And Spiriva Respimat
A batch of almost three dozen new and revised product-specific guidances for generic products has been published by the US Food and Drug Administration, including for rivals to Primatene Mist (epinephrine) metered-dose inhaler and Spiriva Respimat (tiotropium bromide) inhalation spray.
Hikma Taps Celltrion Again To Bring In MENA Stelara Biosimilar
Hikma has signed another partnership agreement to gain Middle East and North Africa commercialization rights to an ustekinumab biosimilar – although not with its US partner, Bio-Thera Solutions.